Terry M. Henry

Terry M. Henry is a life sciences litigator and trial lawyer who represents pharmaceutical, medical device, and other highly regulated companies in complex litigation, regulatory matters, product investigations, and crisis management. He serves as national coordinating and litigation counsel in mass torts, multidistrict litigation, coordinated state proceedings, and other high-stakes disputes involving prescription drugs, medical devices, and consumer products.

Terry develops and executes national defense strategies; coordinates local and national litigation teams; directs expert and scientific defenses; and oversees discovery, dispositive motion practice, settlement strategy, and trial preparation. His experience includes claims involving product design, manufacturing, labeling, warnings, federal preemption, causation, consumer fraud, warranty, and commercial disputes requiring a detailed understanding of the life sciences industry.

Terry also counsels life sciences and other product companies on regulatory compliance, product recalls, post-market issues, risk mitigation, product literature, quality processes, product failure investigations, crisis response, and manufacturing and distribution matters. He assists clients with disputes involving supply chains, manufacturing specifications, quality agreements, industry standards, and the regulatory requirements that govern highly regulated products.

A frequent writer and speaker, Terry addresses pharmaceutical and medical device litigation, mass torts, product liability, recalls, regulatory compliance, and litigation readiness. He is listed in The Best Lawyers in America for Commercial Litigation in Philadelphia for 2024 through 2026.

• “After Monsanto, Defense Bar Must Build Case Against Lohr”, Law360, August 6, 2006.
• “AI in Drug Development Has Entered its “Evidence” Era – and That’s Were the Legal Risk Lives”, For the Defense, Defense Research Institute, August 2026.
• “Monsanto Ruling Bolsters Generic Drug Labeling Preemption”, Law360, July 2026.
• “The Importance of Timely Product Safety Reporting”, Risk Management Magazine, May 28, 2026.
• “Made in America’ EO May Not Survive Section 230”, Law360, April 17, 2026.
• “Coming Soon to an Arbitration New You: Trends in U.S. Mass Tort Litigation and the Insurance Disputes That Are Sure to Follow” Presentation at London Arbitration Week, December 2, 2026.
• “Opioid Enforcement and Litigation Landscape” speaker, ACI Drug and Medical Device Conference, New York, NY, November 30, 2018.
• “A Ray of Hope for Innovator Liability,” Drug & Device Law Blog, April 20, 2018.
• “Why Innovator Liability is the Least Scary Thing About Rafferty,” Law360, April 3, 2018.
• “Understanding a Medical Device Manufacturer’s Broad Duty to Warn”, co-authored with Lauren O’Donnell, Melanie Carter and Naomi Zwillenberg, Medical Device and Diagnostic Industry, Regulatory and Compliance, April 13, 2017.
• “Understanding Defense Strategies for 505(b)(2) Drugs,” co-authored with Ann E. Querns, Law360, March 24, 2017.
• “Practical Tips for Taking the Deposition of an Adversary’s Expert Witness” presentation at the Women in Products Liability CLE Program, ABA Section of Litigation, November 3, 2016.
• “Protecting the Company; Checklist for When Your Company Gets Sued” presentation to Association of Corporate Counsel of Greater Philadelphia, June 3, 2015.

• 2024–2027, Commercial Litigation, Philadelphia, listed in Best Lawyers in America©
• 2012–2019, “Pennsylvania Super Lawyer” in Products Liability, listed in Super Lawyers